# 10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults

> **NCT03875209** · PHASE1 · COMPLETED · sponsor: **David Ho** · enrollment: 54 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **BIOLOGICAL:** 10E8.4/iMab

## Key facts

- **NCT ID:** NCT03875209
- **Lead sponsor:** David Ho
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-08
- **Primary completion:** 2022-03-23
- **Final completion:** 2022-03-23
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-03-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03875209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03875209, "10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03875209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*